Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Files

834259.pdf (2.15 MB)

Document type

Article

Version

Published version

Publication date

2023-10-29

Publication license

cc-by-nc-nd (c) Andrea Bagan Polonio, et al., 2023
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/218972

Exploring the reactivity of bicyclic α-iminophosphonates to access newimidazoline I2 receptor ligands

Journal Title

Authors

Director/Tutor

Journal ISSN

Volume Title

Related resource

https://doi.org/10.1016/j.bioorg.2023.106935

Abstract

Recent studies pointed out the modulation of imidazoline I2 receptors (I2-IR) by selective ligands as a putativestrategy to face neurodegenerative diseases. Foregoing the classical 2-imidazoline/imidazole-containing I2-IRligands, we report a family of bicyclic α-iminophosphonates endowed with high affinity and selectivity upon I2-IR and we advanced a representative compound B06 in preclinical phases. In this paper, we describe the syntheticpossibilities of bicyclic α-iminophosphonates by exploring its ambivalent reactivity, leading to unprecedentedmolecules that showed promising activities as I2-IR ligands in human brain tissues and good BBBpermeation capabilities. After in silico ADME prediction studies, we assessed the neuroprotective properties ofselected compounds and beneficial effect in an in vitro model of Alzheimeŕs and Parkinson’s disease. Along withtheir neuroprotective effect, compounds showed a potent anti-inflammatory response when evaluated in aneuroinflammation cellular model. Moreover, this is the first time that the neuroprotective effects of imidazolineI2-IR ligands in a transgenic Alzheimer’s disease Caenorhabditis elegans strain are investigated. Using a thrashingassay, we found a significant cognition improvement in this in vivo model after treatment with the new bicyclicα-phosphoprolines. Therefore, our results confirmed the need of exploring structurally new I2-IR ligands andtheir potential for therapeutic strategies in neurodegeneration.

Subject

Malalties neurodegeneratives, Envelliment, Neurogenètica

Subject (English)

Neurodegenerative Diseases, Aging, Neurogenetics

Citation

Collections

Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Citation

BAGAN POLONIO, Andrea, et al. Exploring the reactivity of bicyclic α-iminophosphonates to access newimidazoline I2 receptor ligands. Bioorganic Chemistry. 2023. Vol. 142, num. 106935. ISSN 0045-2068. [consulted: 12 of August of 2026]. Available at: https://hdl.handle.net/2445/218972

Export metadata

JSON - METS

Share record